Description

Cotadutide (also known as MEDI0382) is a synthetic peptide that functions as a dual agonist of glucagon-like peptide-1 (GLP-1) and glucagon receptors. It has been investigated for its potential in treating type 2 diabetes mellitus by enhancing insulin secretion and promoting weight loss. Cotadutide is administered via subcutaneous injection and is currently in Phase II clinical trials. Manufactured under GMP conditions with ?99.11% purity, it is suitable for laboratory research applications. Strictly for laboratory research use only.

Product Specifications

Mechanism of Action & Research Applications

Cotadutide acts as a dual agonist of GLP-1 and glucagon receptors, promoting insulin secretion and weight loss. It is utilized in laboratory research to study its effects on glucose metabolism and obesity. Strictly for laboratory research use only.

Side Effects (For Reference Only in Models)

Known side effects from clinical use of GLP-1 and glucagon receptor agonists include nausea, vomiting, and potential risk of pancreatitis. These effects are valuable for interpreting experimental results and ensuring safety in laboratory environments. Strictly for laboratory research use only.

Disclaimer

This product is intended strictly for laboratory research use only. It is not approved for human or veterinary use. Handle according to institutional safety protocols.